14 results on '"Eriksen, Erik Fink"'
Search Results
2. [When should bisphosphonate treatment be discontinued?].
- Author
-
Eriksen EF and Halse J
- Subjects
- Alendronate adverse effects, Alendronate pharmacology, Alendronate therapeutic use, Bone Density drug effects, Bone Density physiology, Bone Density Conservation Agents pharmacology, Bone Density Conservation Agents therapeutic use, Bone Remodeling drug effects, Bone Remodeling physiology, Diphosphonates pharmacology, Diphosphonates therapeutic use, Female, Fractures, Bone prevention & control, Humans, Imidazoles adverse effects, Imidazoles pharmacology, Imidazoles therapeutic use, Risk Factors, Zoledronic Acid, Bone Density Conservation Agents adverse effects, Diphosphonates adverse effects, Osteoporosis drug therapy
- Published
- 2012
- Full Text
- View/download PDF
3. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
- Author
-
Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, and Boonen S
- Subjects
- Aged, Biomarkers metabolism, Bone Density physiology, Bone Density Conservation Agents administration & dosage, Bone Density Conservation Agents adverse effects, Bone Density Conservation Agents therapeutic use, Bone Remodeling physiology, Collagen Type I blood, Diphosphonates administration & dosage, Diphosphonates adverse effects, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Imidazoles administration & dosage, Imidazoles adverse effects, Injections, Intravenous, Injections, Subcutaneous, Least-Squares Analysis, Middle Aged, Osteoporosis, Postmenopausal blood, Osteoporosis, Postmenopausal complications, Osteoporosis, Postmenopausal physiopathology, Osteoporotic Fractures blood, Osteoporotic Fractures complications, Osteoporotic Fractures drug therapy, Osteoporotic Fractures physiopathology, Peptide Fragments blood, Peptides blood, Procollagen blood, Teriparatide administration & dosage, Teriparatide adverse effects, Zoledronic Acid, Diphosphonates therapeutic use, Imidazoles therapeutic use, Osteoporosis, Postmenopausal drug therapy, Teriparatide therapeutic use
- Abstract
Clinical data suggest concomitant therapy with bisphosphonates and parathyroid hormone (PTH) may blunt the anabolic effect of PTH; rodent models suggest that infrequently administered bisphosphonates may interact differently. To evaluate the effects of combination therapy with an intravenous infusion of zoledronic acid 5 mg and daily subcutaneous recombinant human (rh)PTH(1-34) (teriparatide) 20 µg versus either agent alone on bone mineral density (BMD) and bone turnover markers, we conducted a 1-year multicenter, multinational, randomized, partial double-blinded, controlled trial. 412 postmenopausal women with osteoporosis (mean age 65 ± 9 years) were randomized to a single infusion of zoledronic acid 5 mg plus daily subcutaneous teriparatide 20 µg (n = 137), zoledronic acid alone (n = 137), or teriparatide alone (n = 138). The primary endpoint was percentage increase in lumbar spine BMD (assessed by dual-energy X-ray absorptiometry [DXA]) at 52 weeks versus baseline. Secondary endpoints included change in BMD at the spine at earlier time points and at the total hip, trochanter, and femoral neck at all time points. At week 52, lumbar spine BMD had increased 7.5%, 7.0%, and 4.4% in the combination, teriparatide, and zoledronic acid groups, respectively (p < .001 for combination and teriparatide versus zoledronic acid). In the combination group, spine BMD increased more rapidly than with either agent alone (p < .001 versus both teriparatide and zoledronic acid at 13 and 26 weeks). Combination therapy increased total-hip BMD more than teriparatide alone at all times (all p < .01) and more than zoledronic acid at 13 weeks (p < .05), with final 52-week increments of 2.3%, 1.1%, and 2.2% in the combination, teriparatide, and zoledronic acid groups, respectively. With combination therapy, bone formation (assessed by serum N-terminal propeptide of type I collagen [PINP]) increased from 0 to 4 weeks, declined minimally from 4 to 8 weeks, and then rose throughout the trial, with levels above baseline from 6 to 12 months. Bone resorption (assessed by serum β-C-telopeptide of type I collagen [β-CTX]) was markedly reduced with combination therapy from 0 to 8 weeks (a reduction of similar magnitude to that seen with zoledronic acid alone), followed by a gradual increase after week 8, with levels remaining above baseline for the latter half of the year. Levels for both markers were significantly lower with combination therapy versus teriparatide alone (p < .002). Limitations of the study included its short duration, lack of endpoints beyond DXA-based BMD (e.g., quantitative computed tomography and finite-element modeling for bone strength), lack of teriparatide placebo, and insufficient power for fracture outcomes. We conclude that while teriparatide increases spine BMD more than zoledronic acid and zoledronic acid increases hip BMD more than teriparatide, combination therapy provides the largest, most rapid increments when both spine and hip sites are considered., (Copyright © 2011 American Society for Bone and Mineral Research.)
- Published
- 2011
- Full Text
- View/download PDF
4. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
- Author
-
Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, and Lyles KW
- Subjects
- Age Factors, Aged, Bone Density drug effects, Bone Density Conservation Agents adverse effects, Diphosphonates adverse effects, Drug Administration Schedule, Drug-Related Side Effects and Adverse Reactions, Female, Femoral Neck Fractures prevention & control, Humans, Imidazoles adverse effects, Infusions, Intravenous, Medication Adherence, Randomized Controlled Trials as Topic, Spinal Fractures prevention & control, Zoledronic Acid, Bone Density Conservation Agents administration & dosage, Diphosphonates administration & dosage, Fractures, Spontaneous prevention & control, Imidazoles administration & dosage, Osteoporosis drug therapy
- Abstract
Objectives: To determine the efficacy of once-yearly intravenous zoledronic acid (ZOL) 5 mg in reducing risk of clinical vertebral, nonvertebral, and any clinical fractures in elderly osteoporotic postmenopausal women., Design: A post hoc subgroup analysis of pooled data from the Health Outcome and Reduced Incidence with Zoledronic Acid One Yearly (HORIZON) Pivotal Fracture Trial and the HORIZON Recurrent Fracture Trial., Setting: Multicenter, randomized, double-blind, placebo-controlled trials., Participants: Postmenopausal women (aged > or =75) with documented osteoporosis (T-score < or =-2.5 at femoral neck or >/=1 prevalent vertebral or hip fracture) or a recent hip fracture., Intervention: Patients were randomized to receive an intravenous infusion of ZOL 5 mg (n=1,961) or placebo (n=1,926) at baseline and 12 and 24 months., Measurements: Primary endpoints were incidence of clinical vertebral and nonvertebral and any clinical fracture after treatment., Results: At 3 years, incidence of any clinical, clinical vertebral, and nonvertebral fracture were significantly lower in the ZOL group than in the placebo group (10.8% vs 16.6%, 1.1% vs 3.7%, and 9.9% vs 13.7%, respectively) (hazard ratio (HR)=0.65, 95% confidence interval (CI)=0.54-0.78, P<.001; HR=0.34, 95% CI=0.21-0.55, P<.001; and HR=0.73, 95% CI=0.60-0.90, P=.002, respectively). The incidence of hip fracture was lower with ZOL but did not reach statistical significance. The incidence rate of postdose adverse events were higher with ZOL, although the rate of serious adverse events and deaths was comparable between the two groups., Conclusion: Once-yearly intravenous ZOL 5 mg was associated with a significant reduction in the risk of new clinical fractures (vertebral and nonvertebral) in elderly postmenopausal women with osteroporosis.
- Published
- 2010
- Full Text
- View/download PDF
5. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture.
- Author
-
Eriksen EF, Lyles KW, Colón-Emeric CS, Pieper CF, Magaziner JS, Adachi JD, Hyldstrup L, Recknor C, Nordsletten L, Lavecchia C, Hu H, Boonen S, and Mesenbrink P
- Subjects
- Aged, Aged, 80 and over, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Risk Factors, Spinal Fractures mortality, Spinal Fractures prevention & control, Time Factors, Zoledronic Acid, Bone Density drug effects, Bone Density Conservation Agents administration & dosage, Diphosphonates administration & dosage, Hip Fractures mortality, Hip Fractures therapy, Imidazoles administration & dosage, Osteoporosis, Postmenopausal mortality, Osteoporosis, Postmenopausal therapy
- Abstract
Annual infusions of zoledronic acid (5 mg) significantly reduced the risk of vertebral, hip, and nonvertebral fractures in a study of postmenopausal women with osteoporosis and significantly reduced clinical fractures and all-cause mortality in another study of women and men who had recently undergone surgical repair of hip fracture. In this analysis, we examined whether timing of the first infusion of zoledronic acid study drug after hip fracture repair influenced the antifracture efficacy and mortality benefit observed in the study. A total of 2127 patients (1065 on active treatment and 1062 on placebo; mean age, 75 yr; 76% women and 24% men) were administered zoledronic acid or placebo within 90 days after surgical repair of an osteoporotic hip fracture and annually thereafter, with a median follow-up time of 1.9 yr. Median time to first dose after the incident hip fracture surgery was approximately 6 wk. Posthoc analyses were performed by dividing the study population into 2-wk intervals (calculated from time of first infusion in relation to surgical repair) to examine effects on BMD, fracture, and mortality. Analysis by 2-wk intervals showed a significant total hip BMD response and a consistent reduction of overall clinical fractures and mortality in patients receiving the first dose 2-wk or later after surgical repair. Clinical fracture subgroups (vertebral, nonvertebral, and hip) were also reduced, albeit with more variation and 95% CIs crossing 1 at most time points. We concluded that administration of zoledronic acid to patients suffering a low-trauma hip fracture 2 wk or later after surgical repair increases hip BMD, induces significant reductions in the risk of subsequent clinical vertebral, nonvertebral, and hip fractures, and reduces mortality.
- Published
- 2009
- Full Text
- View/download PDF
6. [Osteonecrosis of the jaw].
- Author
-
Eriksen EF
- Subjects
- Bone Density Conservation Agents administration & dosage, Diphosphonates administration & dosage, Humans, Bone Density Conservation Agents adverse effects, Diphosphonates adverse effects, Jaw Diseases chemically induced, Osteonecrosis chemically induced
- Published
- 2009
7. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.
- Author
-
Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, and Reginster JY
- Subjects
- Diphosphonates therapeutic use, Humans, Jaw Diseases therapy, Osteitis Deformans drug therapy, Osteonecrosis therapy, Risk Factors, Diphosphonates adverse effects, Jaw Diseases chemically induced, Osteonecrosis chemically induced, Osteoporosis drug therapy
- Abstract
A potential side effect associated with bisphosphonates, a class of drugs used in the treatment of osteoporosis, Paget's disease and metastatic bone disease, is osteonecrosis of the jaw (ONJ). The incidence of ONJ in the general population is unknown; this rare condition also may occur in patients not receiving bisphosphonates. Case reports have discussed ONJ development in patients with multiple myeloma or metastatic breast cancer receiving bisphosphonates as palliation for bone metastases. These patients are also receiving chemotherapeutic agents that might impair the immune system and affect angiogenesis. The incidence or prevalence of ONJ in patients taking bisphosphonates for osteoporosis seems to be very rare. No causative relationship has been unequivocally demonstrated between ONJ and bisphosphonate therapy. A majority of ONJ occurs after tooth extraction. Furthermore, the underlying risk of developing ONJ may be increased in osteoporotic patients by comorbid diseases. Treatment for ONJ is generally conservative.
- Published
- 2008
- Full Text
- View/download PDF
8. Zoledronic acid and clinical fractures and mortality after hip fracture.
- Author
-
Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, and Boonen S
- Subjects
- Aged, Aged, 80 and over, Bone Density drug effects, Bone Density Conservation Agents administration & dosage, Bone Density Conservation Agents adverse effects, Calcium therapeutic use, Diphosphonates administration & dosage, Diphosphonates adverse effects, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Fractures, Bone epidemiology, Hip Fractures drug therapy, Hip Fractures surgery, Humans, Imidazoles administration & dosage, Imidazoles adverse effects, Infusions, Intravenous, Male, Middle Aged, Survival Analysis, Vitamin D therapeutic use, Zoledronic Acid, Bone Density Conservation Agents therapeutic use, Diphosphonates therapeutic use, Fractures, Bone prevention & control, Hip Fractures mortality, Imidazoles therapeutic use
- Abstract
Background: Mortality is increased after a hip fracture, and strategies that improve outcomes are needed., Methods: In this randomized, double-blind, placebo-controlled trial, 1065 patients were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients were assigned to receive placebo. The infusions were first administered within 90 days after surgical repair of a hip fracture. All patients (mean age, 74.5 years) received supplemental vitamin D and calcium. The median follow-up was 1.9 years. The primary end point was a new clinical fracture., Results: The rates of any new clinical fracture were 8.6% in the zoledronic acid group and 13.9% in the placebo group, a 35% risk reduction with zoledronic acid (P=0.001); the respective rates of a new clinical vertebral fracture were 1.7% and 3.8% (P=0.02), and the respective rates of new nonvertebral fractures were 7.6% and 10.7% (P=0.03). In the safety analysis, 101 of 1054 patients in the zoledronic acid group (9.6%) and 141 of 1057 patients in the placebo group (13.3%) died, a reduction of 28% in deaths from any cause in the zoledronic acid group (P=0.01). The most frequent adverse events in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain. No cases of osteonecrosis of the jaw were reported, and no adverse effects on the healing of fractures were noted. The rates of renal and cardiovascular adverse events, including atrial fibrillation and stroke, were similar in the two groups., Conclusions: An annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and with improved survival. (ClinicalTrials.gov number, NCT00046254 [ClinicalTrials.gov].)., (Copyright 2007 Massachusetts Medical Society.)
- Published
- 2007
- Full Text
- View/download PDF
9. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
- Author
-
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, and Cummings SR
- Subjects
- Aged, Aged, 80 and over, Atrial Fibrillation chemically induced, Biomarkers metabolism, Bone Density drug effects, Bone Density Conservation Agents adverse effects, Diphosphonates adverse effects, Double-Blind Method, Drug Administration Schedule, Female, Fractures, Bone epidemiology, Hip Fractures epidemiology, Hip Fractures prevention & control, Humans, Imidazoles adverse effects, Incidence, Infusions, Intravenous, Risk, Spinal Fractures epidemiology, Spinal Fractures prevention & control, Zoledronic Acid, Bone Density Conservation Agents administration & dosage, Diphosphonates administration & dosage, Fractures, Bone prevention & control, Imidazoles administration & dosage, Osteoporosis, Postmenopausal drug therapy
- Abstract
Background: A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period., Methods: In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes., Results: Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI], 0.24 to 0.38) and reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83). Nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (P<0.001 for all comparisons). Zoledronic acid was also associated with a significant improvement in bone mineral density and bone metabolism markers. Adverse events, including change in renal function, were similar in the two study groups. However, serious atrial fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P<0.001)., Conclusions: A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.), (Copyright 2007 Massachusetts Medical Society.)
- Published
- 2007
- Full Text
- View/download PDF
10. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
- Author
-
Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, and Reid IR
- Subjects
- Administration, Oral, Aged, Aged, 80 and over, Alkaline Phosphatase blood, Bone and Bones drug effects, Etidronic Acid therapeutic use, Follow-Up Studies, Humans, Infusions, Intravenous, Risedronic Acid, Zoledronic Acid, Bone Density Conservation Agents therapeutic use, Bone and Bones metabolism, Diphosphonates therapeutic use, Etidronic Acid analogs & derivatives, Imidazoles therapeutic use, Osteitis Deformans metabolism
- Abstract
Unlabelled: A single 5-mg infusion of zoledronic acid restores biochemical markers of bone turnover into the reference range in the majority of patients with Paget's disease and maintains biochemical remission for at least 2 years. This effect is largely independent of pretreatment disease activity and prior bisphosphonate therapy., Introduction: Zoledronic acid (ZOL) is a potent bisphosphonate that produces a rapid and complete control of the increased bone turnover of Paget's disease. Long-term control of disease activity is an important aim of treatment in the hope that this will reduce the risk of complications such as deformity, fracture, and degenerative joint disease., Materials and Methods: This study compares the ability of ZOL 5 mg given as a 15-minute intravenous infusion with risedronate (RIS) 30 mg daily by mouth for 60 days to maintain long-term control of bone turnover. No bisphosphonate was given during the extension study. All patients (n = 296) who achieved a therapeutic response, defined as normalization or a >75% reduction in the total alkaline phosphatase (total ALP) excess above the midpoint of the reference range, were eligible for inclusion., Results: ZOL maintained the mean level of total ALP at the middle of the reference range, whereas those treated with risedronate showed a linear increase in total ALP from the 6-month post-treatment time-point. Both treatments resulted in a linear relationship between the 6-month nadir and 24-month total ALP. The relationship for RIS was shifted upward, showing that for a given level of post-treatment biochemical activity, bone turnover increased with time. This was in contrast to the ZOL-treated patients where total ALP generally remained unchanged over this 18-month extension period. A similar pattern of response was seen with the other bone turnover markers., Conclusions: ZOL maintains bone turnover within the reference range over 24 months from the initiation of treatment. A reduction in the incidence and severity of long-term complications may require persistent normalization of bone turnover over many years, and this now seems a realistic possibility with ZOL.
- Published
- 2007
- Full Text
- View/download PDF
11. Efficacy and Safety of a Once-Yearly Intravenous Zoledronic Acid 5 mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older
- Author
-
Boonen, Steven, Black, Dennis M., Colón-Emeric, Cathleen S., Eastell, Richard, Magaziner, Jay S., Eriksen, Erik Fink, Mesenbrink, Peter, Haentjens, Patrick, and Lyles, Kenneth W.
- Subjects
Bone Density Conservation Agents ,Diphosphonates ,Drug-Related Side Effects and Adverse Reactions ,Age Factors ,Imidazoles ,Zoledronic Acid ,Article ,Drug Administration Schedule ,Femoral Neck Fractures ,Medication Adherence ,Fractures, Spontaneous ,Bone Density ,Humans ,Osteoporosis ,Spinal Fractures ,Female ,Infusions, Intravenous ,Aged ,Randomized Controlled Trials as Topic - Abstract
To determine the efficacy of once-yearly intravenous zoledronic acid (ZOL) 5 mg in reducing risk of clinical vertebral, nonvertebral, and any clinical fractures in elderly osteoporotic postmenopausal women.A post hoc subgroup analysis of pooled data from the Health Outcome and Reduced Incidence with Zoledronic Acid One Yearly (HORIZON) Pivotal Fracture Trial and the HORIZON Recurrent Fracture Trial.Multicenter, randomized, double-blind, placebo-controlled trials.Postmenopausal women (agedor =75) with documented osteoporosis (T-scoreor =-2.5 at femoral neck or/=1 prevalent vertebral or hip fracture) or a recent hip fracture.Patients were randomized to receive an intravenous infusion of ZOL 5 mg (n=1,961) or placebo (n=1,926) at baseline and 12 and 24 months.Primary endpoints were incidence of clinical vertebral and nonvertebral and any clinical fracture after treatment.At 3 years, incidence of any clinical, clinical vertebral, and nonvertebral fracture were significantly lower in the ZOL group than in the placebo group (10.8% vs 16.6%, 1.1% vs 3.7%, and 9.9% vs 13.7%, respectively) (hazard ratio (HR)=0.65, 95% confidence interval (CI)=0.54-0.78, P.001; HR=0.34, 95% CI=0.21-0.55, P.001; and HR=0.73, 95% CI=0.60-0.90, P=.002, respectively). The incidence of hip fracture was lower with ZOL but did not reach statistical significance. The incidence rate of postdose adverse events were higher with ZOL, although the rate of serious adverse events and deaths was comparable between the two groups.Once-yearly intravenous ZOL 5 mg was associated with a significant reduction in the risk of new clinical fractures (vertebral and nonvertebral) in elderly postmenopausal women with osteroporosis.
- Published
- 2010
12. Impact of osteonecrosis of the jaw on osteoporosis management: executive summary of an ESCEO and Foundation for Research on Osteoporosis and other Bone Diseases Working Group Meeting.
- Author
-
Rizzoli, René, Burlet, Nansa, Cahall, David, Delmas, Pierre D., Eriksen, Erik Fink, Felsenberg, Dieter, Grbic, John, Jontell, Mats, Landesberg, Regina, Laslop, Andrea, Matton, Peter, Papapoulos, Socrates, Sezer, Orhan, Sprafka, Michael, and Reginster, Jean-Yves
- Subjects
OSTEONECROSIS ,OSTEOPOROSIS ,DISEASES in older people ,DIPHOSPHONATES ,DISEASE risk factors ,DENTAL care - Abstract
The first reports of osteonecrosis of the jaw in patients taking bisphosphonates to reduce excessive bone resorption were published in 2003. Subsequent reports raised concern and resulted in manufacturers writing letters of caution to physicians and dentists. Recommendations were issued by the US FDA, and the European Agency for the Evaluation of Medicinal Products requested that pharmaceutical companies update their product information and package leaflets. The European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and the Foundation for Research on Osteoporosis and other Bone Diseases Working Group Meeting was convened on 14 December 2006 in Geneva, Switzerland, to review the available data and published guidelines on this rare but serious condition. The purpose of the meeting was to assess the impact of osteonecrosis of the jaw on the management of osteoporosis. The discussion focused on the current definition of osteonecrosis of the jaw, its epidemiology and pathophysiology, as well as identifying potential risk factors. Agreement was also reached on best practice in terms of diagnosis and management. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
13. Bisphosphonates as a treatment modality in osteoarthritis.
- Author
-
Eriksen, Erik Fink, Shabestari, Maziar, Ghouri, Asim, and Conaghan, Philip G.
- Subjects
- *
DIPHOSPHONATES , *BONES , *ARTICULAR cartilage , *BONE marrow , *MODAL logic , *INTRA-articular injections , *OSTEOCHONDRITIS ,BONE marrow examination - Abstract
Osteoarthritis (OA) is affecting large proportions of the population worldwide. So far, no effective disease modifying drug has been developed for this disease, limiting the therapeutic options to pain medications, physiotherapy and ultimately surgical approaches, mainly joint implant surgery. In vitro and animal studies have demonstrated that bisphosphonates have the potential to become effective modalities for the treatment of OA. This group of pharmacological agents modulates crucial aspects of OA pathogenesis (subchondral bone turnover and loss, bone marrow edema formation, cartilage degeneration and synovitis), and have shown clear efficacy in animal models of OA. Human studies have, however, so far been disappointing with only one of six clinical studies showing clear short-term efficacy. Possible reasons for these discrepancies will be discussed. • Preclinical studies suggest significant effects of bisphosphonates on a wide variety of factors involved in OA pathogenesis • Bisphosphonates reduce bone turnover and reduction of subchondral bone turnover seems to reduce articular cartilage deterioration • Bone marrow lesions, which play an integral role in OA pathogenesis, are areas of high bone turnover and increased vascularization, - two characteristics amenable to modulation by bisphosphonate treatment • Bisphosphonate treatment has shown disease modifying effects in a wide variety of animal models • Future studies of bisphosphoantes in OA should focus on appropriate dosing and improved selection of suitable patients with this heterogenous disease [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.
- Author
-
Tsourdi, Elena, Langdahl, Bente, Cohen-Solal, Martine, Aubry-Rozier, Bérengere, Eriksen, Erik Fink, Guañabens, Nuria, Obermayer-Pietsch, Barbara, Ralston, Stuart H., Eastell, Richard, and Zillikens, M. Carola
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *DIPHOSPHONATES , *OSTEOPOROSIS treatment , *TREATMENT of fractures , *BONE density - Abstract
Introduction The optimal duration of osteoporosis treatment is controversial. As opposed to bisphosphonates, denosumab does not incorporate into bone matrix and bone turnover is not suppressed after its cessation. Recent reports imply that denosumab discontinuation may lead to an increased risk of multiple vertebral fractures. Methods The European Calcified Tissue Society (ECTS) formed a working group to perform a systematic review of existing literature on the effects of stopping denosumab and provide advice on management. Results Data from phase 2 and 3 clinical trials underscore a rapid decrease of bone mineral density (BMD) and a steep increase in bone turnover markers (BTMs) after discontinuation of denosumab. Clinical case series report multiple vertebral fractures after discontinuation of denosumab and a renewed analysis of FREEDOM and FREEDOM Extension Trial suggests, albeit does not prove, that the risk of multiple vertebral fractures may be increased when denosumab is stopped due to a rebound increase in bone resorption. Conclusion There appears to be an increased risk of multiple vertebral fractures after discontinuation of denosumab although strong evidence for such an effect and for measures to prevent the occurring bone loss is lacking. Clinicians and patients should be aware of this potential risk. Based on available data, a re-evaluation should be performed after 5 years of denosumab treatment. Patients considered at high fracture risk should either continue denosumab therapy for up to 10 years or be switched to an alternative treatment. For patients at low risk, a decision to discontinue denosumab could be made after 5 years, but bisphosphonate therapy should be considered to reduce or prevent the rebound increase in bone turnover. However, since the optimal bisphosphonate regimen post-denosumab is currently unknown continuation of denosumab can also be considered until results from ongoing trials become available. Based on current data, denosumab should not be stopped without considering alternative treatment in order to prevent rapid BMD loss and a potential rebound in vertebral fracture risk. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.